Many people can afford to pay hundreds of dollars a month for a GLP-1 drug, he says, but not most of our patients. Any primary care doctor would hate to see a potent new weapon against chronic disease fall out of reach, but its especially hard for Rind because he knows the data so well
Acta Dermatol Venereol, 176(suppl): 7-12
However, brand-name versions remain financially out of reach for most patients
*Compared to absorption through the skin
A negative scan with an undetectable thyroglobulin clearly represents total ablation
The drug was also well tolerated, with mostly mild or moderate gastrointestinal-related adverse events that Roche said were "consistent with the safety profile of the incretin drug class," and will now progress to phase 2